• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Autophagy inhibition potentiates anti-cancer activity of Sunitinib in kidney cancer cells.

作者信息

Patergnani Simone, Zampieri Pietro, Bianchi Nicoletta, Ippolito Carmelo, Gafà Roberta, Lanza Giovanni, Wieckowski Mariusz R, Pinton Paolo, Aguiari Gianluca

机构信息

Department of Medical Sciences, Laboratory for Technologies of Advanced Therapies, University of Ferrara, 44121, Ferrara, Italy.

Department of Neuroscience and Rehabilitation, University of Ferrara, 44121, Ferrara, Italy.

出版信息

Biol Direct. 2025 Jul 15;20(1):82. doi: 10.1186/s13062-025-00671-6.

DOI:10.1186/s13062-025-00671-6
PMID:40665378
Abstract
摘要

相似文献

1
Autophagy inhibition potentiates anti-cancer activity of Sunitinib in kidney cancer cells.自噬抑制增强了舒尼替尼在肾癌细胞中的抗癌活性。
Biol Direct. 2025 Jul 15;20(1):82. doi: 10.1186/s13062-025-00671-6.
2
Atractylenolide I inhibits angiogenesis and reverses sunitinib resistance in clear cell renal cell carcinoma through ATP6V0D2-mediated autophagic degradation of EPAS1/HIF2α.白术内酯I通过ATP6V0D2介导的EPAS1/HIF2α自噬降解抑制透明细胞肾细胞癌的血管生成并逆转舒尼替尼耐药性。
Autophagy. 2025 Mar;21(3):619-638. doi: 10.1080/15548627.2024.2421699. Epub 2024 Nov 4.
3
Chloroquine potentiates the anticancer effect of sunitinib on renal cell carcinoma by inhibiting autophagy and inducing apoptosis.氯喹通过抑制自噬和诱导凋亡增强舒尼替尼对肾细胞癌的抗癌作用。
Oncol Lett. 2018 Mar;15(3):2839-2846. doi: 10.3892/ol.2017.7635. Epub 2017 Dec 19.
4
Sunitinib-resistant renal cell carcinoma cell-derived exosomes promote facilitation of tumor progression via secretion of the lncRNA SNHG16.对舒尼替尼耐药的肾癌细胞衍生的外泌体通过分泌长链非编码RNA SNHG16促进肿瘤进展。
Hum Cell. 2025 May 13;38(4):100. doi: 10.1007/s13577-025-01228-5.
5
Genome-wide CRISPR/Cas9 screening identifies PTGR2 as a potential therapeutic target for sunitinib resistance in clear cell renal cell carcinoma.全基因组CRISPR/Cas9筛选确定PTGR2为透明细胞肾细胞癌中舒尼替尼耐药的潜在治疗靶点。
Sci Rep. 2025 Jul 19;15(1):26263. doi: 10.1038/s41598-025-12192-3.
6
Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines.特西罗莫司与酪氨酸激酶抑制剂联合应用于肾细胞癌和内皮细胞系。
J Cancer Res Clin Oncol. 2012 Jun;138(6):907-16. doi: 10.1007/s00432-012-1162-x. Epub 2012 Feb 10.
7
A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.系统评价和荟萃分析比较不同全身治疗方案对非透明细胞肾细胞癌的疗效和不良反应。
Eur Urol. 2017 Mar;71(3):426-436. doi: 10.1016/j.eururo.2016.11.020. Epub 2016 Dec 8.
8
Nilotinib in combination with sunitinib renders MCL-1 for degradation and activates autophagy that overcomes sunitinib resistance in renal cell carcinoma.尼罗替尼联合舒尼替尼使 MCL-1 降解，并激活自噬，从而克服肾细胞癌对舒尼替尼的耐药性。
Cell Oncol (Dordr). 2024 Aug;47(4):1277-1294. doi: 10.1007/s13402-024-00927-9. Epub 2024 Feb 23.
9
LncRNA HOTAIR induces sunitinib resistance in renal cancer by acting as a competing endogenous RNA to regulate autophagy of renal cells.长链非编码RNA HOTAIR通过作为竞争性内源性RNA调节肾细胞自噬，诱导肾癌对舒尼替尼产生耐药性。
Cancer Cell Int. 2020 Jul 24;20:338. doi: 10.1186/s12935-020-01419-0. eCollection 2020.
10
Immunotherapy for metastatic renal cell carcinoma.转移性肾细胞癌的免疫治疗
Cochrane Database Syst Rev. 2017 May 15;5(5):CD011673. doi: 10.1002/14651858.CD011673.pub2.

本文引用的文献

1
Molecular Mechanisms of Drug Resistance in Clear Cell Renal Cell Carcinoma.透明细胞肾细胞癌耐药的分子机制
Cancers (Basel). 2025 May 10;17(10):1613. doi: 10.3390/cancers17101613.
2
Wild-Type p53 Regulates Apoptosis of Human Breast Cancer Cells.野生型p53调控人乳腺癌细胞的凋亡。
Discov Med. 2024 Dec;36(191):2445-2453. doi: 10.24976/Discov.Med.202436191.225.
3
Autophagy in cancer development, immune evasion, and drug resistance.自噬在癌症发展、免疫逃逸及耐药性中的作用
Drug Resist Updat. 2025 Jan;78:101170. doi: 10.1016/j.drup.2024.101170. Epub 2024 Nov 15.
4
The Wolfram-like variant WFS1 destabilizes MAM and compromises autophagy and mitophagy in human and mice.类 Wolfram 变异型 WFS1 使 MAM 不稳定，并损害人和小鼠的自噬和线粒体自噬。
Autophagy. 2024 Sep;20(9):2055-2066. doi: 10.1080/15548627.2024.2341588. Epub 2024 Apr 23.
5
Twenty years of Gendicine® rAd-p53 cancer gene therapy: The first-in-class human cancer gene therapy in the era of personalized oncology.20年的健择®重组人5型腺病毒载体抑癌基因（rAd-p53）癌症基因治疗：个性化肿瘤学时代的首个同类人癌症基因治疗。
Genes Dis. 2023 Oct 31;11(4):101155. doi: 10.1016/j.gendis.2023.101155. eCollection 2024 Jul.
6
Autophagy inhibition potentiates energy restriction-induced cell death in hepatocellular carcinoma cells.自噬抑制增强了能量限制诱导的肝癌细胞死亡。
IUBMB Life. 2024 Aug;76(8):577-588. doi: 10.1002/iub.2816. Epub 2024 Mar 18.
7
The dual role of autophagy in the regulation of cancer treatment.自噬在癌症治疗调控中的双重作用。
Amino Acids. 2024 Feb 4;56(1):7. doi: 10.1007/s00726-023-03364-4.
8
Revisiting mechanisms of resistance to immunotherapies in metastatic clear-cell renal-cell carcinoma.重新审视转移性透明细胞肾细胞癌对免疫疗法的耐药机制。
Cancer Drug Resist. 2023 May 30;6(2):314-326. doi: 10.20517/cdr.2023.09. eCollection 2023.
9
Autophagy and Breast Cancer: Connected in Growth, Progression, and Therapy.自噬与乳腺癌：在生长、进展和治疗中相互关联。
Cells. 2023 Apr 14;12(8):1156. doi: 10.3390/cells12081156.
10
A Phase II Open-Label Trial of Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS-Mutant Non-Small Cell Lung Cancer.Binimetinib 和羟氯喹治疗晚期 KRAS 突变型非小细胞肺癌患者的 II 期开放标签试验。
Oncologist. 2023 Jul 5;28(7):644-e564. doi: 10.1093/oncolo/oyad106.